Healing & RecoveryLimited ResearchResearch Only

Cartalax

Cartilage Bioregulator

Not medical advice. For educational and research reference only.

Typical Dose

Varies by protocol

Route

Injectable / Oral

Cycle

10–20 day cycles

Storage

Formulation-dependent

What is Cartalax?

Investigational peptide discussed for cartilage and connective-tissue support.

Research / educational reference. Educational research index only — not medical advice. Literature maturity is not a verdict on whether a compound works in people. Community reports are not evidence of efficacy.

Evidence at a glance

Derived · maturity-1.0

Human efficacy is unproven unless an approved label or completed published efficacy program says otherwise. Counts reflect indexed literature volume/kind — never a verdict on effect.

Literature maturity

nascent 0/100

PubMed hits

0

CT.gov trials

0

Strong-human apps

0

Sample papers

0

Sample articles by era

    Application grades (curated)

    • Human-grade apps0
    • Animal / in-vitro0
    • Mechanistic0

    Does literature support studied applications?

    Grades reflect cited literature posture — not a treatment recommendation. Community notes are never efficacy evidence.

    ApplicationCited evidenceGradeCommunity
    Bioregulator peptide research

    Limited indexed English clinical literature for common wellness claims.

    Anecdotal onlyCommunity reports vary; not evidence of efficacy.

    Pharmacology

    Identity & chemistry

    Formula
    C12H19N3O8
    Molar mass
    333.29 Da
    InChIKey
    KXEVYGKATAMXJJ-ACZMJKKPSA-N

    Identity cross-checked with PubChem where available. Compass HTML used only as a bootstrap checklist — not republished as product copy.

    Storage & stability

    Lyophilized
    2–8°C; lyophilized typical shelf 18–24 months
    Reconstituted
    2–8°C; in-use window often 14–30 days (product-dependent)
    Tell-tale degradation
    • !Cloudiness, clumping, or particles after mixing
    • !Discoloration versus the expected clear/colorless (or labeled) solution
    • !Failed or incomplete reconstitution of lyophilized cake

    Educational estimates. Prefer product labeling and peptide shelf-life tool.

    Lab handling posture

    Research / educational handling notes only. Not a substitute for an SDS.

    • •Use PPE appropriate for peptide powder/solution handling
    • •Avoid inhalation of lyophilized powder; handle spills per institutional policy
    • •Do not present research materials as medicines

    Research Indications

    Tissue RepairMost Effective

    Demonstrated acceleration of wound healing and soft tissue repair in research

    Gut HealthEffective

    Research shows beneficial effects on intestinal lining and GI function

    Joint SupportEffective

    Associated with reduced joint inflammation and improved mobility

    Muscle RecoveryModerate

    May support faster recovery from muscle strains and exercise stress

    Research Protocols

    These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

    GoalDoseFrequencyRoute
    Starting Dose100 mcgOnce dailySubcutaneous injection
    Standard Dose250 mcgOnce dailySubcutaneous injection

    Peptide & Drug Interactions

    Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

    TB-500 / BPC-157 (stack)Compatible
    NSAIDs (Ibuprofen, Naproxen)Caution
    CorticosteroidsCaution
    AnticoagulantsMonitor
    GH SecretagoguesCompatible
    NAD+Compatible

    How to Reconstitute & Inject

    Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

    1. 1

      Remove Cartalax vial from refrigeration and allow to reach room temperature (15–20 minutes)

    2. 2

      Clean vial top with alcohol swab and allow to air dry completely

    3. 3

      Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

    4. 4

      Inject BAC water slowly down the side of the vial — do not aim directly at the powder

    5. 5

      Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

    6. 6

      Allow 2–3 minutes for full dissolution — solution should be clear and colorless

    7. 7

      Draw calculated dose into an insulin syringe for subcutaneous injection

    8. 8

      Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

    9. 9

      Store reconstituted solution refrigerated (2–8°C) and use within 28 days

    What to Expect

    Week 1–2

    Initial anti-inflammatory effects begin. Reduced pain and swelling in target area.

    Week 2–4

    Improved tissue mobility and reduced discomfort. Early healing acceleration.

    Week 4–8

    Significant recovery milestones. Stronger tissue repair and functional improvement.

    Week 8–12

    Near-complete healing in many cases. Improved strength and tissue integrity.

    Side Effects & Safety

    • Generally well-tolerated in research settings
    • Mild nausea with higher doses
    • Injection site redness or discomfort
    • Rare: Dizziness or lightheadedness
    • Potential effect on blood pressure (monitor if hypertensive)

    FDA Status & Regulatory Info

    Research Only

    Investigational peptide discussed for cartilage and connective-tissue support.

    Rx Required: No
    503A Ban: No
    Telehealth: N/A
    Full FDA Status Tracker

    Frequently Asked Questions

    Research References

    External links for education only. We do not control third-party content.

    Community-reported data

    The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

    Community Intelligence

    What 27 users report

    27 community reports

    Overall experience

    From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

    Favorable 57% · Mixed 43% · Unfavorable overall 0%

    Most reported benefits

    Benefits users selected when logging a favorable or mixed check-in.

    Recovery
    180

    Self-reported dose per injection

    Median bucket: 2+ mg · Most common: 2+ mg

    Reports span 2 to ≥ 2 mg (open-ended top bucket)

    2+ mg
    180

    Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

    How repeat users are trending

    Among repeat reporters, 88% said they felt similar to their last entry, 13% more positive, and 0% more negative.

    Overall, repeat reporters leaned more positive than their previous entry.

    Median gap between entries: 197 days · Based on 24 repeat reporters

    Share Your Experience

    Rate Cartalax in the PeptIQ app and help the community make informed decisions.

    Educational information only

    This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.

    PeptIQ app

    Log your Cartalax protocol in PeptIQ

    Turn this Cartalax guide into a living protocol — doses, vials, and history in one place.

    Track CartalaxOpen web app

    iOS, Android, and web

    Ask PeptIQ

    Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

    Start the quizOr try Peptide X Quiz →

    Quick Facts

    Route
    Injectable / Oral
    Availability
    Research only
    Rx Required
    No
    503A Ban
    No
    Browse peptide education

    Talk with a clinician

    PeptIQ is education only. We do not sell peptides or list vendors. Discuss Cartalax with a licensed healthcare provider — not medical advice, not a prescription.

    Download PeptIQ